Catalina Lizano-Barrantes

Mrs. Catalina Lizano-Barrantes

Health Services Research Group, IMIM-Hospital del Mar Medical Research Institute, Barcelona, Spain
+2
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 October 2023 in European Respiratory Review
Verified
Journal Article
Open access
PDF file
KMKarina Mayoral
Karina Mayoral
CLCatalina Lizano-Barrantes
Catalina Lizano-Barrantes
VZVíctor Zamora
Víctor Zamora
APAngels Pont
Angels Pont
CMCarme Miret
Carme Miret
MFMontserrat Ferrer
Montserrat Ferrer
Background: We aim to assess the impact of montelukast on paediatric patients with asthma/allergic rhinitis, measured using patient-reported outcome measures, compared with other treatments or placebo.Methods: Protocol registration CRD42020216098 (www.crd.york.ac.uk/PROSPERO). MEDLINE and Embase databases were used to conduct the search. Two authors independently selected studies and extracted data, and a third reviewer resolved discrepancies. Meta-analyses were constructed to estimate the standardised mean difference (SMD) using a random-effects model.Results: Out of 3937 articles identified, 49 studies met the inclusion criteria, mostly randomised clinical trials (sample sizes: 21–689 patients). The SMD of change pooled estimators for the global, mental and physical domains of health-related quality of life were not statistically significant. For daytime and night-time symptoms scores, the SMD (95% CI) was in favour of inhaled corticosteroids (−0.12, −0.20– −0.05 and −0.23, −0.41– −0.06, respectively). The pooled estimator for global asthma symptoms was better for montelukast when compared with placebo (0.90, 0.44–1.36).Conclusions: The synthesis of the available evidence suggests that, in children and adolescents, montelukast was effective in controlling asthma symptoms when compared with placebo, but inhaled corticosteroids were superior in controlling symptoms, especially at night-time. These findings of our systematic review concur with current guidelines for asthma treatment.

19 October 2025 in ADMET and DMPK
Verified
Journal Article
Open access
PDF file
RVRonny Vargas
Ronny Vargas
NMNoelia Martinez-Martinez
Noelia Martinez-Martinez
CLCatalina Lizano-Barrantes
Catalina Lizano-Barrantes
JPJorge Andrés Pacheco-Molina
Jorge Andrés Pacheco-Molina
Encarna Garcia-MontoyaEncarna Garcia-Montoya
Encarna Garcia-Montoya
MSMarc Suñé-Pou
Marc Suñé-Pou
Background and purpose: The delivery of therapeutics to the central nervous system (CNS) remains a major challenge due to the restrictive nature of the blood-brain barrier (BBB), a key evolutionary feature that preserves brain homeostasis. This review seeks to synthesize current knowledge on BBB composition, physiology, and transport mechanisms, and critically analyses drug delivery strategies aimed at overcoming this barrier and enabling effective CNS therapies. Approach: We conducted a comprehensive narrative review integrating evidence on BBB anatomy, transport and permeability mechanisms, drug delivery optimization strategies, with a particular focus on nanotechnology-based systems, and preclinical evaluation models. Key results: We highlight how a deeper understanding of BBB architecture and dynamic regulation can inform rational design of targeted strategies. Drug delivery approaches are summarized and compared, with emphasis on the potential of nanotechnology-based platforms to enhance CNS drug delivery. Translational considerations, including scalability, reproducibility, and regulatory requirements, are critically addressed. Major challenges identified include receptor saturation, competition with endogenous ligands, disease-specific variability in BBB permeability, and the limited predictive value of current preclinical models. Emerging tools, such as organ-on-chip (for evaluation) and microfluidic mixing (for manufacturing nanomaterials), offer promising means to improve physiological relevance and accelerate translation. Conclusion: Progress in BBB research has laid the groundwork for innovative therapies, but significant hurdles remain. Advancing CNS drug delivery will require collaborative work refining transport-targeting mechanisms, developing standardized preclinical models, and integrating fundamental research, applied nanomedicine, and regulatory science to open new opportunities for treating neurological and psychiatric disorders and brain tumours.

2 January 2021 in Quality of Life Research
Verified
Journal Article
Closed access
PDF file
KMK. Mayoral
K. Mayoral
OGO. Garin
O. Garin
MCM. A. Caballero-Rabasco
M. A. Caballero-Rabasco
MPM. Praena-Crespo
M. Praena-Crespo
ASALBERTO BERCEDO SANZ
ALBERTO BERCEDO SANZ
Alexandra L DimaAlexandra L Dima
Alexandra L Dima

23 January 2025 in Quality of Life Research
Verified
Journal Article
Open access
PDF file
CAClara Amat-Fernandez
Clara Amat-Fernandez
OGOlatz Garin
Olatz Garin
RLRicardo Luer-Aguila
Ricardo Luer-Aguila
YPYolanda Pardo
Yolanda Pardo
RBRenata Briseño
Renata Briseño
MFMontserrat Ferrer
Montserrat Ferrer
Purpose: To systematically review qualitative studies on outcomes, needs, experiences, preferences, concerns and health-related quality of life (HRQoL) of people surviving cancer in Europe in the last decade. Methods: Protocol registered (https://www.crd.york.ac.uk/PROSPERO, ID575065). Inclusion criteria: studies with qualitative methods, constructs related to HRQoL, and adults surviving cancer in Europe. The search was conducted in PubMed and Scopus since 2013. Abstracts and full text were revised, data extracted and study risk of bias assessed independently by two researchers. The primary outcomes were the themes arising from each study. A thematic analysis stratified according to the study objective was undertaken by grouping themes into categories. Results: Of 18,256 articles identified, 43 fulfilled the inclusion criteria: 16 studies with a generic objective and 27 with specific objectives. Seven categories (57 themes) emerged from the studies with a generic focus: Clinical Management (n = 16), Symptoms and Physical Function (n = 5), Psychological Function (n = 21), Social Function (n = 18), HRQoL (n = 3), Life Disruption (n = 6), and Individual Factors (n = 1). The 12 studies focused on treatment and care experiences stand out among those with specific objectives, with most themes fitting into the same seven categories. Conclusions: Results clearly showed the predominance of the social and psychological function domains over physical domains among people surviving cancer, additionally identifying specific needs in clinical management, such as information and communication, and relationship with and support from professionals. Therefore, these aspects should be incorporated into the evaluation of patient-centred initiatives for people surviving cancer. Limitations: only two databases were searched, and most European countries were not represented.

CLCatalina Lizano-Barrantes
Catalina Lizano-Barrantes
OGOlatz Garin
Olatz Garin
Alexandra L DimaAlexandra L Dima
Alexandra L Dima
EGEric van Ganse
Eric van Ganse
MBMarijn de Bruin
Marijn de Bruin
MFMontserrat Ferrer
Montserrat Ferrer
There is a need for instruments designed for patients with asthma to self-report their performance of inhaling steps. We aimed to develop an accessible and easy-to-use patient-reported tool for inhaler technique assessment, which could also serve as a training and monitoring resource for any type of inhaler device, and to evaluate its feasibility, validity, and reliability in adults with asthma. The development was based on literature review and pilot testing with clinicians and patients. The Inhaler Technique Questionnaire (InTeQ) asks about the frequency of performing five steps when using inhalers (on a five-point Likert scale). We analyzed data from adults with persistent asthma (n = 361). We examined the measurement model using Mokken scaling analysis, construct validity by assessing hypotheses on expected discrimination among known groups, and reliability based on internal consistency and reproducibility. Means of the InTeQ items were in the range of 0.23–1.61, and coefficients of homogeneity were above the cutoff point, demonstrating the unidimensionality of the scale. Known groups’ global score differences were statistically significant between patients reporting having “Discussed in detail” or having “Not discussed/Only in general” the inhaler technique with their healthcare providers (p = 0.023). The Cronbach’s alpha coefficient was 0.716, and the intraclass correlation coefficient was 0.775. The InTeQ is a feasible, valid, and reliable instrument for self-reporting inhaler technique on any type of device.

6 March 2023 in World Journal of Pediatrics
Verified
Journal Article
Open access
PDF file
CLCatalina Lizano-Barrantes
Catalina Lizano-Barrantes
OGOlatz Garin
Olatz Garin
Alexandra L DimaAlexandra L Dima
Alexandra L Dima
KMKarina Mayoral
Karina Mayoral
APAngels Pont
Angels Pont
MBMarijn de Bruin
Marijn de Bruin